Foghorn Therapeutics (FHTX) Short term Debt (2019 - 2020)
Foghorn Therapeutics (FHTX) posted quarterly Short term Debt of $6.0 million for Q3 2020, up 44.27% quarter-over-quarter from $4.2 million in Q4 2019.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Short term Debt (2019 - 2020) Analysis & Trends
Foghorn Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $6.0 million for Q3 2020.
- In Q3 2020, Short term Debt changed N/A year-over-year to $6.0 million; the TTM figure through Sep 2020 stood at $6.0 million (changed N/A YoY), while the FY2019 annual figure was $4.2 million, changed N/A from the prior year.
- Short term Debt for Q3 2020 stood at $6.0 million, up from $4.2 million in the prior quarter.
- The five-year high for Short term Debt was $6.0 million in Q3 2020, with the low at $4.2 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 347.14 Mn | 279.06 Mn | - |